Deni Iskandar

Mr. Deni Iskandar

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
GCGabriella J Caren
Gabriella J Caren
DIDeni Iskandar
Deni Iskandar
DPDian Ae Pitaloka
Dian Ae Pitaloka
RARizky Abdulah
Rizky Abdulah
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
The current coronavirus disease 2019 (COVID-19) situation might deteriorate the efforts to eliminate tuberculosis (TB) in Indonesia. This study aimed to review the COVID-19 pandemic disruption on the management of TB treatment in Indonesia. We identified several disruptions due to the pandemic on TB control management. Firstly, there is a potential decrease in the funding for TB treatment. Financial disruptions caused by the COVID-19 pandemic have led to further setbacks. In many countries, including Indonesia, financial and other resources have been reallocated from TB to the COVID-19 response. Secondly, it has been highlighted that all TB services, including case detection and rapid diagnostic, have been disrupted by the pandemic. Thirdly, the pandemic would be associated with the lower quality of care and treatment for TB in Indonesia. It might decrease the enthusiasm of patients with TB, multi-drug resistant (MDR)-TB, and TB-human immunodeficiency virus (HIV) to visit TB hospitals because of social distancing measures by the government. Finally, the COVID-19 pandemic also has impacted critical activities of monitoring, evaluation, and surveillance. There are several lessons from other countries about managing TB treatment during the pandemic, such as combining screening for COVID-19 and TB by applying x-ray technology and artificial intelligence-based software. In addition, the use of telemedicine or telehealth in TB treatment is also beneficial to deliver medication, assess patients’ progress, and inform prevention strategies. To reach the target with the end TB strategy, the government of Indonesia can adopt the World Health Organization’s (WHO’s) comprehensive strategies, such as integrated, patient-centered TB care and prevention strategies; bold policies and supportive systems; and intensified research and innovations.

24 November 2022 in The Lancet Global Health
Verified
Journal Article
Open access
DIDeni Iskandar
Deni Iskandar
ASAuliya A Suwantika
Auliya A Suwantika
IPIvan S Pradipta
Ivan S Pradipta
MPMaarten J Postma
Maarten J Postma
JBJob F M van Boven
Job F M van Boven
The global incidence of tuberculosis is decreasing, yet it remains high in Indonesia. The Indonesian National Tuberculosis Program facilitates mandatory notification, which enables early detection and treatment, minimises complications, prevents transmission, and decreases deaths. This study aimed to assess the characteristics, trends, and economic burden of notified drug-susceptible tuberculosis cases registered in this system from 2017 to 2019. We performed a multiyear cross-sectional study focusing on drug-susceptible tuberculosis notified cases, incidence, geographical tuberculosis case distribution, treatment outcomes, and costs in Indonesia using data from Sistem Informasi Tuberkulosis (2017-19). The settings were Indonesian health-care facilities that provide tuberculosis control programmes and services. Eligible patients were those who were diagnosed with drug-susceptible tuberculosis and notified to Sistem Informasi Tuberkulosis. Between 2017 and 2019, notified cases increased from 429 219 to 523 614 individuals, corresponding to an increase in incidence from 167 cases per 100 000 to 196 cases per 100 000. In 2019, more than 250 cases per 100 000 inhabitants were notified in Jakarta, North Sulawesi, Gorontalo, and Papua. Treatment success rate increased from 363 098 (84·60%) of 429 219 in 2017 to 452 966 (86·51%) of 523 614 in 2019, with a relatively stable mortality, changing from 3·15% to 3·05%. HIV status was increasingly confirmed, with unknown status decreasing from 66·21% to 43·68%. The costs of visits and monitoring and drug regimens were relatively stable, with total direct medical costs slightly increasing from US$39·40 to $40·40 per case. Progress was made on drug-susceptible tuberculosis management in Indonesia. However, further intensified efforts, including case-finding, optimising diagnosis, and cost-effective tuberculosis management are required if Indonesia is to achieve the 2025 WHO End Tuberculosis Strategy target incidence of fewer than 55 cases per 100 000 people. These data are an important starting point for understanding drug-susceptible tuberculosis dynamics in Indonesia and optimising its management. Directorate General of Higher Education; Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia.

7 July 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
DIDeni Iskandar
Deni Iskandar
FSF. D. A. Suryanegara
F. D. A. Suryanegara
JBJ. F. M. van Boven
J. F. M. van Boven
MPM. J. Postma
M. J. Postma
Objective: This study aims to systematically review the content and potential effects of clinical pharmacy services in tuberculosis (TB) care management.Methods: Searches were performed in PubMed, Embase, Cochrane, Scopus, and Web of Science databases following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study characteristics and outcomes were extracted, and clinical pharmacy service components were characterized using the Descriptive Elements of Pharmacist Intervention Characterization Tool.Results: Twenty articles were included for full-text assessment, of which 10 fulfilled inclusion criteria, comprising 1,168 patients (N = 39 to 258 per study). These articles included five prospective cohort studies, two case–control studies, two quasi-experimental studies, and one cross-sectional study. Intervention foci within clinical pharmacy services were medication adherence (50%), medication safety (40%), education to patients/caregivers regarding needs/beliefs (30%), optimizing medication/therapy effectiveness (30%), emphasizing HRQoL (10%), and drug selections (10%). The three most frequently applied interventions were drug information/patient counseling (80%), adverse drug reaction monitoring (50%), and drug use evaluation (20%). Based on the World Health Organization (WHO) outcome classification, treatment success ranged from 72% to 93%, with higher cure outcomes (53%–86%) than treatment completion (7%–19%). Other outcomes, including isoniazid metabolites, medication counts, sputum conversion, adherence/compliance, knowledge, and quality of life, were better in the intervention group than those in comparator groups, and/or they improved over time. Risk of bias analysis indicated that the included studies were not comparable to a randomized clinical trial.Conclusion: Clinical pharmacy services as single or composite interventions potentially improve TB outcomes, but its evidence is still inconsistent and limited due to the lack of randomized controlled studies using the WHO outcome classification.Systematic review registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=199028, identifier CRD42020199028.

10 November 2023 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
DIDeni Iskandar
Deni Iskandar
IPIvan S Pradipta
Ivan S Pradipta
AAAni Anggriani
Ani Anggriani
MPMaarten J Postma
Maarten J Postma
JBJob F M van Boven
Job F M van Boven
Introduction Optimal pharmacological treatment of tuberculosis (TB) requires a multidisciplinary team, yet the hospital pharmacist’s role is unclear. We aimed to analyse hospital pharmacist-provided clinical pharmacy services (CPS) implementation in TB care. Method A nationwide survey-based online cross-sectional study was conducted on hospital pharmacists in Indonesia from 1 November 2022 to 22 November 2022. Outcomes were the extent of pharmacists’ involvement in multidisciplinary TB care, TB-related CPS provided and views on TB-related CPS. The probability of pharmacists’ involvement in multidisciplinary TB teams was assessed using logistic regression. Results In total, 439 pharmacists (mean age 31.2±6.22 years, 78% female) completed the survey. Thirty-six per cent were part of multidisciplinary TB care, and 23% had TB-related tasks. Adherence monitoring (90%) and drug use evaluation (86%) were the most conducted TB-related CPS. Pharmacists’ views on TB-related CPS implementation were generally positive, except for financial incentives. Work experience (OR 1.99, 95% CI 1.09 to 3.61), ever received TB-related training (OR 3.51, 95% CI 2.03 to 6.14) and specific assignments to provide TB-related CPS (OR 8.42, 95% CI 4.99 to 14.59) significantly increased pharmacist involvement in multidisciplinary TB care. Conclusion Around one-third of hospital pharmacists are part of multidisciplinary TB care, with medication adherence and drug use monitoring as primary tasks. Pharmacists’ experience, training, assignment to provide TB-related CPS and financial incentives are key elements for further implementation in multidisciplinary TB care. Pharmacists should proactively support current TB care and conduct operational research, sharing data with healthcare peers and fostering a collaborative multidisciplinary TB care team.

2 April 2019 in Indonesian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
RNRizki Siti Nurfitria
Rizki Siti Nurfitria
RERima Nur Adillah Effendi
Rima Nur Adillah Effendi
DIDeni Iskandar
Deni Iskandar
An effort to reduce medication errors is to use drugs prescription electronically[1,2,4]. However, there needs to be an evaluation of this system, because this system is not free from errors in medication. This study aimed to find out the description of prescribing flow, to examine electronic prescription completeness, and find out the potential medication errors that occur in the prescribing phase of electronic prescription using prescribing indicators[1,5,9,10]. This study used observational method by taking general practice outpatient prescription data of March 2018 in a company health service located in Bandung and analyzed descriptively[6,7,8]. Electronic prescription of medicines at this health care was made and inputted by doctors. When an error occured on a computer system, the doctor would prescribe it manually so that the patient can still be served. Incompleteness of the most common recipe was on administrative requirements where all prescriptions did not listed the doctor's practice permit, patient's gender, patient's weight, telephone number of the place of practice, and patient's contact number. Medication errors had the most potential for the occurrence of prescription writing with two or more drugs interacting and this error was classified as category D according to The National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP).

13 November 2023
Verified
Thesis
Closed access
PDF file
DIDeni Iskandar
Deni Iskandar